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measuring 1 cm each were noted at the vaginal fornix, in the 3 and 9
o'clock positions. A third similar lesion was noted in the lower third of
the vagina in the 7 o'clock position. An endometrial biopsy showed a
FIGO grade I endometrioid adenocarcinoma in a background of complex
hyperplasia with atypia. CT abdomen and pelvis showed no evidence of
extrauterine disease or lymphadenopathy. The patient was taken to the
operating room for a robot-assisted laparoscopic hysterectomywith bi-Introduction my and excision of the lesion at the lower third of the vagina. AThe use of minimally invasive surgery has been incorporated into
the surgical management of gynecologic malignancies. The beneﬁts as-
sociated with minimally invasive surgery in gynecologic oncology in-
clude shorter hospitalization, increased patient satisfaction, and
decreased blood loss and postoperative infections. The introduction of
robotic surgical systems has provided improved visualization and preci-
sion allowing the performance of more complicated procedures. The
possibility of recurrent disease at the port site after minimally invasive
surgery for gynecologic malignancy has been well documented in the
literature (Childers et al., 1994). There have been reports of ovarian ad-
enocarcinomas, squamous cell cervical carcinomas and uterine adeno-
carcinomas metastasizing to the laparoscopy ports and the incidence
of port site metastasis after laparoscopy is about 1% which is compara-
ble to the risk of metastases to drain sites and surgical incisions
post-laparotomy. The data on port site recurrence after robotic surgery
are limited. Recently, a case of port site recurrence after robotic hyster-
ectomy and staging for uterine papillary serous carcinomawas reported
(Rauff and S.Ng, 2012). Here we report the ﬁrst case of port site recur-
rence after robotic hysterectomy and lymph node dissection for endo-
metrial adenocarcinoma of endometrioid histology.
Case
A 72-year old, multiparous woman presentedwith a history of post-
menopausal bleeding for one year. Clinical examination revealed a25, Brooklyn, NY 11203, USA.
dis).
Inc. Open access under CC BY-NC-SA licenselateral salpingo-oophorectomy, pelvic and paraaortic lymphadenecto-
V-care uterine manipulator was placed. The da Vinci® surgical system
(Intuitive Surgical) with 3 arms was used. A 12 mm supra-umbilical
camera port and two 8 mm instrument ports were placed 10 cm lateral
to the umbilicus and a 12 mm assistant port was placed at the right
upper quadrant.
CO2 pneumoperitoneum of 15 mmHg was maintained throughout
the procedure. The ﬁrst specimen included the uterus, fallopian tubes
and ovaries and was removed intact through the vagina. The lymph
nodes were removed through the assistant port. Specimen bags were
not used. The operative time was 2.5 h and the estimated blood loss
was 50 cm3. The ﬁnal pathology was that of endometrioid type adeno-
carcinoma, FIGO Grade III (Fig. 1). The tumor size was 13 cm and the
depth of invasion was 2 of 2.1 cm of myometrium (98%). No
lymphovascular invasion was seen. The vaginal lesion was positive for
metastatic endometrioid adenocarcinoma. Lymph nodeswere negative.
The patientwas assigned a FIGO (2009) stage IIIB (Creasman, 2009).
The postoperative treatment plan included whole pelvis radiation
and interstitial brachytherapy followed by chemotherapy with
Carboplatin and Taxol. The patient received external beamwhole pelvic
radiation therapy followed by interstitial brachytherapy. The port sites
were outside the radiatedﬁeld. At the completion of radiation, complete
regression of the metastatic vaginal lesions was achieved. Three weeks
later the patient reported pain on the abdominal wall at the site of the
right lateral instrumental port.
The clinical exam revealed a 2 × 3 cm tender mobile subcutaneous
nodule at the port site. A CT abdomen and pelvis was obtained and re-
vealed tissue density in the abdominal wall at the site of the right lateral
8 mm port and no evidence of intraabdominal disease (Fig. 2). Chest
X-ray was unremarkable. A local excision was performed in the operat-
ing room and the pathology conﬁrmed recurrent endometrial adeno-
carcinoma of endometrioid type (Fig. 3). The peritoneal cavity was not
breached during the excision of the port site tumor. One week later
the patient presented to the emergency room with abdominal pain,.
Fig. 1. Primary endometrial adenocarcinoma of endometrioid histology. Fig. 3. Excised tumor from the right lateral port site. The histologic appearance is similar to
the primary endometrioid adenocarcinoma.
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bowel obstruction with transition point at the terminal ileum, probably
due to radiation enteritis. A 1.7 cm × 1.3 cm hypodense lesion on the
surface of the liver, not present on the previous scan was noted. She
was admitted and conservative management with nasogastric suction
and intravenous ﬂuids was initiated. On the second day of her hospital-
ization, she was found unresponsive. An attempt for cardiopulmonary
resuscitation was not successful. Possible cause of death is pulmonary
embolism.
Discussion
The reported incidence of port-site metastasis after robotic surgery
for gynecologic malignancy is around 1% which is comparable to tradi-
tional laparoscopic surgery (Nodofor et al., 2011; Zivanovic et al., 2008).
Here we describe a case of advanced endometrioid adenocarcinoma
(Stage IIIB) with port-site metastasis after robotic hysterectomy and
lymph node dissection. To our knowledge this is the ﬁrst reportedFig. 2. CT abdomen–pelvis. Hyperdense lesion in the right anterolateral abdominal wall.case of port-sitemetastasis after robotic surgery for endometrial adeno-
carcinoma of endometrioid type.
A number of factors have been implicated in the development of
port-site metastasis including aerosolization of tumor cells, direct
contamination and tumor implantation at the port site, local immune
response and the surgical technique. Advanced disease with ascites
and peritoneal seeding conveys a higher risk (Hopkins et al., 1999;
Ramirez et al., 2003). Preventive measures that have been proposed
include minimizing tissue trauma at the transfer of instruments, rins-
ing the trocars and the instrument tips in povidone–iodine, topical
treatment of port sites with cytotoxic agents (i.e. 5-FU), the use of
specimen bags for retrieval, removing all intra-abdominal ﬂuid before
trocar removal, and closure of peritoneal trocar sites of 10 mm or
more (Ramirez et al., 2004; Wang et al., 1999).
Despite the numerous hypothetical explanations, the pathogenesis
of port site metastasis remains unclear. In our case, the large tumor
size (13 cm) and the high metastatic potential as evidenced by the
vaginal metastases are possible contributing factors. It is reasonable to
assume that large tumor volume is associated with increased risk of
spillage of tumor cells during the manipulations of the specimen. High
concentrations of angiogenesis and growth factors at the port site due
to the healing process can promote the implantation and proliferation
of malignant cells with high metastatic potential. In addition, failure of
activation of the immune system encourages port-site tumor growth.
Preclinical data suggest that the effect of laparoscopic surgery on the
antitumor immune response differs from that of open surgery. CO2
pneumoperitoneum inhibits macrophage and neutrophil function and
reduces TNF production. These effects are evident not only on the peri-
toneal environment but also systemically (Ramirez et al., 2003).
Previously reported cases of port site recurrence after robotic sur-
gery, involved multifocal disease with aggressive histology. At the
time of recurrence, the disease had spread in multiple sites and the
independent prognostic signiﬁcance of the port site tumor was mini-
mal (Nodofor et al., 2011). Similarly, in our case the abdominal
imaging revealed metastatic disease on the surface of the liver and
the clinical presentation of small bowel obstruction raises suspicion
for peritoneal seeding below the resolution of the CT. Therefore, the
impact of the port site metastatic tumor on the outcome may not be
signiﬁcant and the beneﬁt from any preventive measures may be
limited.
However, staging for uterine adenocarcinoma of endometrioid
histology is the most common indication for robotic surgery in gyne-
cologic oncology and consideration to surgical principles that could
decrease the risk of port-site recurrence should be given.
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vaginally could decrease the possibility of spillage of tumor cells at
the port sites. A lower CO2 pneumoperitoneum pressure and avoid-
ance of subcutaneous emphysema could further decrease the risk of
dissemination and implantation of tumor cells in the subcutaneous
tissue. Slow and controlled release of the pneumoperitoneum with
the trocars in place could limit the contamination of the laparoscopic
incisions with tumor cells. Finally, limiting the number of the port
sites to four and reserving the third robotic arm for technically chal-
lenging cases (i.e. extreme obesity, suboptimal uterine manipulation,
multiple adhesions) could be considered.
Robot-assisted minimally invasive surgery is a new advancement
in the surgical management of gynecologic malignancies and the ev-
idence with regards to beneﬁts and complications is scant. Staging
for uterine adenocarcinoma of endometrioid histology is a very
common indication for the use of robotic surgery and has been asso-
ciated with favorable outcomes especially in the obese population.
In agreement with prior experience from conventional laparoscopic
staging (Muntz et al., 1999) our case indicates that tumor spread at
the port site is possible. Although the recurrence at the port site is
frequently an indicator of widespread disease and the impact of
any preventive measures on survival is questionable, the implemen-
tation of surgical practices that decrease the risk of this complica-
tion without signiﬁcantly affecting operative time and blood loss
should be encouraged.Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
References
Childers, J.M., Aqua, K.A., Surwit, E.A., Hallum, A.V., Hatch, K.D., 1994. Abdominal-wall
tumor implantation after laparoscopy for malignant conditions. Obstet. Gynecol.
84, 765–769.
Rauff, S., S.Ng, J., 2012. Port-site recurrence in a patient undergoing robot-assisted gy-
necologic cancer surgery for endometrial cancer — a case report. Gynecol. Oncol.
Case Rep. 2, 127–129.
Creasman, W., 2009. Revised FIGO staging for carcinoma of the endometrium. Int. J.
Gynaecol. Obstet. 105 (2), 109.
Nodofor, B.T., Soliman, P.T., Schmeler, K.M., Nick, A.M., Frumovitz, M., Ramirez, P.T.,
2011. Rate of port-site metastasis is uncommon in patients undergoing robotic sur-
gery for gynecological malignancies. Int. J. Gynecol. Cancer 21 (5), 936–940.
Zivanovic, O., Sonoda, Y., Diaz, J.P., Levine, D.A., Brown, C.L., Chi, D.S., Barakat, R.R., Abu-
Rustum, N.R., 2008. The rate of port-site metastases after 2251 laparoscopic proce-
dures in women with underlying malignant disease. Gynecol. Oncol. 111 (3).
Hopkins, M.P., Dulai, R.M., Occhino, A., Holda, S., 1999. The effects of carbon dioxide
pneumoperitoneum on seeding of tumor in port. Am. J. Obstet. Gynecol. 181,
1329–1333.
Ramirez, P.T., Wolf, J.K., Levenback, C., 2003. Laparoscopic port-site metastases: etiology
and prevention. Gynecol. Oncol. 91, 179–189.
Ramirez, P.T., Frumovitz,M.,Wolf, J.K., Levenback, C., 2004. Laparoscopic port-sitemetastases
in patients with gynaecological malignancies. Int. J. Gynecol. Cancer 14 (6), 1070–1077.
Wang, P.H., Yuan, C.C., Lin, G., Ng, H.T., Chao, H.T., 1999. Risk factors contributing to
early occurrence of port site metastases of laparoscopic surgery for malignancy.
Gynecol. Oncol. 72, 38–44.
Muntz, H.G., Goff, B.A., Madsen, B.L., Yon, J.L., 1999. Port-site recurrence after laparoscopic
surgery for endometrial carcinoma. Obstet. Gynecol. 3 (5/2), 807–809.
